Clinical Trials Logo

Clinical Trial Summary

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05047133
Study type Interventional
Source Ascension Genesys Hospital
Contact Jacob Hinkley, DO, MS
Phone 810-606-5669
Email jacob.hinkley2@ascension.org
Status Recruiting
Phase Phase 2/Phase 3
Start date September 1, 2021
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT02631980 - HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ? Phase 3
Completed NCT02701946 - Efficacy of Modified Robert Jones Bandages on Reducing Invisible Blood Loss After Total Knee Arthroplasty N/A
Terminated NCT00885924 - Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery Phase 4
Completed NCT02427412 - Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty Phase 4
Completed NCT01475669 - Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery Phase 3
Completed NCT01622946 - The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach Phase 4
Not yet recruiting NCT05889494 - Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients N/A
Recruiting NCT05774717 - Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis Phase 1